How have CNBX shares performed in 2024?

CNBX Pharmaceuticals' stock was trading at $0.0142 at the start of the year. Since then, CNBX shares have decreased by 17.6% and is now trading at $0.0117. View the best growth stocks for 2024 here .

Are investors shorting CNBX Pharmaceuticals?

CNBX Pharmaceuticals saw a increase in short interest during the month of March. As of March 31st, there was short interest totaling 300 shares, an increase of 200.0% from the March 15th total of 100 shares. Based on an average daily trading volume, of 56,600 shares, the days-to-cover ratio is currently 0.0 days. View CNBX Pharmaceuticals' Short Interest .

When did CNBX Pharmaceuticals' stock split?

CNBX Pharmaceuticals shares reverse split before market open on Thursday, May 12th 2022. The 1-120 reverse split was announced on Thursday, May 12th 2022. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, May 12th 2022. An investor that had 100 shares of stock prior to the reverse split would have 1 shares after the split.

What other stocks do shareholders of CNBX Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other CNBX Pharmaceuticals investors own include Gran Tierra Energy (GTE) , Organigram (OGI) , KushCo (KSHB) , Pennsylvania Real Estate Investment Trust (PEI) , Medical Marijuana (MJNA) , Auxly Cannabis Group (CBWTF) , American Cannabis (AMMJ) , GreenGro Technologies (GRNH) , MassRoots (MSRT) and Surna (SRNA) .

How do I buy shares of CNBX Pharmaceuticals?

Shares of CNBX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

OTCMKTS:CNBX

CNBX Pharmaceuticals (CNBX) Stock Price, News & Analysis

→ REVEALED: Elon Musk’s Secret A.I. Facility? (From InvestorPlace) (Ad)

Free CNBX Stock Alerts

$0.01

0.00 (0.00%)

(As of 04/15/2024 ET)

Compare

Today's Range: $0.0115
▼
$0.0135
50-Day Range: $0.0106
▼
$0.0180
52-Week Range: $0.01
▼
$0.05

Volume: 81,642 shs
Average Volume: 259,415 shs
Market Capitalization: N/A

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: N/A

Stock Analysis Chart Financials SEC Filings Short Interest

Get CNBX Pharmaceuticals alerts:

Ad InvestorPlace

REVEALED: Elon Musk’s Secret A.I. Facility?

I recently shot this video outside what could be Elon Musk’s biggest secret. What’s happening inside these walls is so important that our government has declared it a matter of national security.

Click here to see the details because there’s a lot of money at stake.

About CNBX Pharmaceuticals Stock (OTCMKTS:CNBX)

CNBX Pharmaceuticals Inc., a clinical stage company, engages in the discovery, development, and commercialization of novel cannabinoid-based products and technologies for the treatment of cancer. Its lead product candidate is Cannabics SR, an oral capsule developed for the treatment of patients with advanced cancer and cancer anorexia cachexia syndrome. The company is also developing various drug candidates, including PLP-33 for the treatment of lateral spreading or sessile, and colorectal polyps during colonoscopy; BRST-33 to treat breast cancer; MLN-33 for the treatment of Melanoma; and PRST-33 to treat prostate cancer. In addition, it is developing RCC-33, an oral capsule containing a formulation of cannabinoids for the treatment of colorectal cancer; and Cannabics CDx, an ex-vivo drug sensitivity test. The company was formerly known as Cannabics Pharmaceuticals Inc. and changed its name to CNBX Pharmaceuticals Inc. in March 2022. CNBX Pharmaceuticals Inc. was incorporated in 2004 and is based in Bethesda, Maryland. The company is a subsidiary of Cannabics Inc.

CNBX Stock Price History

30 days | 90 days | 365 days | Advanced Chart

CNBX Stock News Headlines

November 24, 2023 | benzinga.com

CNBX Pharmaceuticals Stock (OTC:CNBX) Dividends: History, Yield and Dates

November 5, 2023 | morningstar.com

CNBX Pharmaceuticals Inc CNBX

April 16, 2024 | InvestorPlace (Ad)

“Forget Tesla, this is Elon’s Next Big Thing”

According to Forbes, this breakthrough could define the future of AI. Most people don’t know about it… Because it was found 750 miles away from Silicon Valley.

October 10, 2023 | investing.com

CNBX Historical Data

July 28, 2023 | finance.yahoo.com

CNBX - CNBX Pharmaceuticals Inc.

November 8, 2022 | benzinga.com

CNBX Acquires A Controlling Interest In Cancer Immunotherapy Developer

November 8, 2022 | finance.yahoo.com

CNBX to Enter the Cancer Immunotherapy Market After Acquiring a Controlling Interest in TaGeza Biopharma

October 18, 2022 | finance.yahoo.com

CNBX Files New PCT Patent Application For Cannabinoids-Based Neoadjuvant Cancer Therapy

April 16, 2024 | InvestorPlace (Ad)

“Forget Tesla, this is Elon’s Next Big Thing”

According to Forbes, this breakthrough could define the future of AI. Most people don’t know about it… Because it was found 750 miles away from Silicon Valley.

October 13, 2022 | finance.yahoo.com

CNBX Patent Application "Composition and Method for Treating Cancer with Cannabinoids" Enters National Phase in US and Israel

September 28, 2022 | finance.yahoo.com

CNBX Pharmaceuticals Announces New Patent Granted in Australia

September 12, 2022 | reuters.com

CNBX Pharmaceuticals Inc

August 16, 2022 | ca.finance.yahoo.com

CNBX Pharmaceuticals Inc. (CNBX)

June 10, 2022 | benzinga.com

CNBX Pharmaceuticals (OTC:CNBXD), Earnings Estimates, EPS, and Revenue

June 10, 2022 | benzinga.com

CNBX Pharmaceuticals (OTC:CNBXD), Analyst Ratings, Price Targets, Predictions

June 7, 2022 | finance.yahoo.com

CNBX Pharmaceuticals Inc. (CNBXD)

May 31, 2022 | finance.yahoo.com

CNBX Pharmaceuticals Release a New Corporate Presentation

May 14, 2022 | barrons.com

CNBX Pharmaceuticals Inc.

May 5, 2022 | seekingalpha.com

CNBX pharma granted patent in Hong Kong for cancer therapy

May 5, 2022 | finance.yahoo.com

CNBX Pharmaceuticals Granted Patent in Hong Kong

April 4, 2022 | msn.com

Novartis to save at least $1 billion by 2024 thanks to simplified structure

April 4, 2022 | msn.com

Vertex Pharma sees positive results in Phase 2 trials of new non-opioid pain killer

April 4, 2022 | cnbc.com

What to watch today: Wall Street looks higher; Twitter soars on Elon Musk stake

April 4, 2022 | msn.com

Stocks making the biggest moves in the premarket: Twitter, Tesla, Starbucks and more

April 1, 2022 | cnbc.com

CNBC Transcript: Johnson & Johnson CEO Joaquin Duato Speaks with CNBC’s Meg Tirrell Live During CNBC’s Healthy Returns Summit Today

April 1, 2022 | cnbc.com

What to watch today: Wall Street set to wrap up strong month but weak quarter

April 1, 2022 | msn.com

Stocks making the biggest moves premarket: Walgreens, Baidu, Novavax and others

See More Headlines

Receive CNBX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for CNBX Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange: OTCMKTS
Sector: Medical
Industry: Biotechnology
Sub-Industry: Cannabis
Current Symbol: OTCMKTS:CNBX
CUSIP: N/A
CIK: 1343009
Web: www.cannabics.com
Phone: (877) 424-2429
Fax: N/A
Employees: 2
Year Founded: N/A

Profitability

EPS (Most Recent Fiscal Year): N/A
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: N/A
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: N/A
Return on Assets: N/A

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: N/A
Quick Ratio: N/A

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: N/A
Price / Book: N/A

Miscellaneous

Outstanding Shares: N/A
Free Float: N/A
Market Cap: N/A
Optionable: Not Optionable
Beta: N/A

The 10 Best AI Stocks to Own in 2024

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report

Key Executives

Mr. Gabriel Yariv (Age 48)
President, COO & Executive Chairman
Comp: $241.67k
Mr. Uri Ben-Or CPA (Age 54)
CPA, M.B.A., MBA, Chief Financial Officer
Comp: $40.32k
Mr. Eyal Barad (Age 59)
Co-Founder, CEO & Director
Comp: $269.15k
Dr. Sanja Goldberg (Age 48)
Chief Technology Officer
Comp: $48.12k
Noam Permont
Vice President of Public Relations & Investor Relations
Dr. Sigalit Ariely-Portnoy Ph.D. (Age 60)
Senior Advisor of Regulation, Validation & Quality and Member of Advisory Board
Dr. Tal Mofkadi Ph.D.
Financial Advisor & Member of Advisory Board
Mr. Yasha Borstein (Age 61)
Chief Data Officer
Dr. Yaakov Waksman (Age 72)
Head of Cannabidiol Research
Dr. Ilya Reznik M.D.
Head of Neuropsychiatry Development

Key Competitors

View All Competitors

CNBX Stock Analysis - Frequently Asked Questions

How have CNBX shares performed in 2024?: CNBX Pharmaceuticals' stock was trading at $0.0142 at the start of the year. Since then, CNBX shares have decreased by 17.6% and is now trading at $0.0117.
View the best growth stocks for 2024 here.
Are investors shorting CNBX Pharmaceuticals?: CNBX Pharmaceuticals saw a increase in short interest during the month of March. As of March 31st, there was short interest totaling 300 shares, an increase of 200.0% from the March 15th total of 100 shares. Based on an average daily trading volume, of 56,600 shares, the days-to-cover ratio is currently 0.0 days.
View CNBX Pharmaceuticals' Short Interest.
When did CNBX Pharmaceuticals' stock split?: CNBX Pharmaceuticals shares reverse split before market open on Thursday, May 12th 2022. The 1-120 reverse split was announced on Thursday, May 12th 2022. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, May 12th 2022. An investor that had 100 shares of stock prior to the reverse split would have 1 shares after the split.

What other stocks do shareholders of CNBX Pharmaceuticals own?: Based on aggregate information from My MarketBeat watchlists, some companies that other CNBX Pharmaceuticals investors own include Gran Tierra Energy (GTE), Organigram (OGI), KushCo (KSHB), Pennsylvania Real Estate Investment Trust (PEI), Medical Marijuana (MJNA), Auxly Cannabis Group (CBWTF), American Cannabis (AMMJ), GreenGro Technologies (GRNH), MassRoots (MSRT) and Surna (SRNA).
How do I buy shares of CNBX Pharmaceuticals?: Shares of CNBX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (OTCMKTS:CNBX) was last updated on 4/16/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

CNBX Pharmaceuticals (CNBX) Stock Price, News & Analysis

About CNBX Pharmaceuticals Stock (OTCMKTS:CNBX)

CNBX Stock Price History

CNBX Stock News Headlines

Industry, Sector and Symbol

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

CNBX Stock Analysis - Frequently Asked Questions

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info